NCT00024622|CompletedFDA Drug
PET Scanning in Parkinson s Disease
Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia
Loading search results
Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia
Sponsor study identifier
Secondary identifiers
observational
502
1 country
1
Study Start
March 15, 2002
Actual (reported)Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThis is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-\[F-18\] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans....
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 23, 2001
Actual (reported)September 24, 2001
Actual (reported)March 15, 2002
Actual (reported)To explore with positron emission tomography (PET) the pathophysiology and cerebral consequences of dopaminergic dysregulation.
To explore with positron emission tomography (PET) the pathophysiology and cerebral consequences of dopaminergic dysregulation.
Ongoing
Healthy volunteers.
Patients with Parkinsons
Patients - schizophrenia spectrum disorders
O-15 Water
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson's disease (both familial and sporadic), and those with schizophrenia spectrum disorders.
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Eisenberg DP, Blackman RK, Tietcheu MG, Kohn PD, Bettina JS, Kolachana B, Gregory MD, Berman KF. Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals. Mol Psychiatry. 2025 Jun;30(6):2645-2652. doi: 10.1038/s41380-024-02873-2. Epub 2024 Dec 27.
Ianni AM, Eisenberg DP, Boorman ED, Constantino SM, Hegarty CE, Gregory MD, Masdeu JC, Kohn PD, Behrens TE, Berman KF. PET-measured human dopamine synthesis capacity and receptor availability predict trading rewards and time-costs during foraging. Nat Commun. 2023 Sep 30;14(1):6122. doi: 10.1038/s41467-023-41897-0.
Karen F Berman, M.D.
National Institute of Mental Health (NIMH)
502 participants (actual enrollment reported by the registry).
First Submitted
September 23, 2001
First Posted
September 24, 2001
Study Start
March 15, 2002
Actual (reported)CATIE- Schizophrenia Trial
Contact the study team to confirm eligibility.
Eisenberg DP, Kohn PD, Hegarty CE, Smith NR, Grogans SE, Czarapata JB, Gregory MD, Apud JA, Berman KF. Clinical correlation but no elevation of striatal dopamine synthesis capacity in two independent cohorts of medication-free individuals with schizophrenia. Mol Psychiatry. 2022 Feb;27(2):1241-1247. doi: 10.1038/s41380-021-01337-1. Epub 2021 Nov 17.
Eisenberg DP, Kohn PD, Hegarty CE, Ianni AM, Kolachana B, Gregory MD, Masdeu JC, Berman KF. Common Variation in the DOPA Decarboxylase (DDC) Gene and Human Striatal DDC Activity In Vivo. Neuropsychopharmacology. 2016 Aug;41(9):2303-8. doi: 10.1038/npp.2016.31. Epub 2016 Feb 29.
Last Updated
October 29, 2026
Record last verified: 2026-10-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: